Inventor · disambiguated record
Guoqing Cao
Also filed as: CAO GUOQING
20 granted patents·18 pending applications·62 citations·filing 2004–2023
92Inventor score
Files withJIANGSU HENGRUI MEDICINE CO11SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD7MINGHUI PHARMACEUTICAL HANGZHOU LTD5Shanghai hengrui pharmaceutical co ltd5CHANGCHUN JETTY AUTOMOTIVE TECH CO LTD3
Top patents by PatentIndex Score
38 records- 0192US10344090B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jul 9, 2019·15 cites·27 claims
- 0290US11208484B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Granted Dec 28, 2021·4 cites·9 claims
- 0390US10206980B2IL-15 heterodimeric protein and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Feb 19, 2019·20 cites·19 claims
- 0489US11866500B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2021·Granted Jan 9, 2024·1 cites·17 claims
- 0586US11365255B2PD-1 antibody, antigen-binding fragment thereof, and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2019·Granted Jun 21, 2022·2 cites·12 claims
- 0683US10815304B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Oct 27, 2020·3 cites·25 claims
- 0782US12435144B2Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancersSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2023·Granted Oct 7, 2025·0 cites·19 claims
- 0878US7470705B2Compounds and methods for treating dyslipidemiaLILLY CO ELI·Filed 2005·Granted Dec 30, 2008·4 cites·18 claims
- 0976US9637484B2Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted May 2, 2017·5 cites·20 claims
- 1073US9862765B2IL-17A binding agent and uses thereofShanghai hengrui pharmaceutical co ltd·Filed 2014·Granted Jan 9, 2018·2 cites·25 claims
- 1169US11525005B2Anti-CD40 antibody, antigen binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Dec 13, 2022·1 cites·25 claims
- 1265US7749992B2Compounds and methods for treating dislipidemiaLILLY CO ELI·Filed 2004·Granted Jul 6, 2010·3 cites·14 claims
- 1364US9828653B2Method for recycling lead oxide-containing waste materialCHILWEE POWER CO LTD·Filed 2014·Granted Nov 28, 2017·1 cites·18 claims
- 1459US11780923B2PD-L1 antibody, antigen-binding fragment thereof and medical application thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 1558US2025145723A1Antigen-binding protein and use thereofMINGHUI PHARMACEUTICAL HANGZHOU LTD·Filed 2023·Application pending·0 cites
- 1655US9828654B2Method for directly recovering lead oxide used for a lead-acid battery cathode from waste lead pasteCHILWEE POWER CO LTD·Filed 2014·Granted Nov 28, 2017·1 cites·14 claims
- 1755US2024139327A1Prodrug compound, preparation method therefor and use thereofMINGHUI PHARMACEUTICAL HANGZHOU LTD·Filed 2022·Application pending·0 cites
- 1852US2025132582A1Dead time determination method, charging driving circuit and apparatus, and device and mediumCHANGCHUN JETTY AUTOMOTIVE TECH CO LTD·Filed 2022·Application pending·0 cites
- 1952US2025135890A1Discharge control method and apparatus, electronic device, and storage mediumCHANGCHUN JETTY AUTOMOTIVE TECH CO LTD·Filed 2022·Application pending·0 cites
- 2052US2024358848A1Antitumor compound and use thereofMINGHUI PHARMACEUTICAL HANGZHOU LTD·Filed 2022·Application pending·0 cites
- 2152US2024380222A1Circuit and method for suppressing power supply starting surge, charging apparatus, and storage mediumCHANGCHUN JETTY AUTOMOTIVE TECH CO LTD·Filed 2022·Application pending·0 cites
- 2251US2024132515A1Toxin molecule suitable for antibody-drug conjugateMINGHUI PHARMACEUTICAL HANGZHOU LTD·Filed 2022·Application pending·0 cites
- 2350US2024309093A1Antigen binding protein and use thereofMINGHUI PHARMACEUTICAL HANGZHOU LTD·Filed 2022·Application pending·0 cites
- 2448US2021009706A1Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2547US2020054594A1Pharmaceutical composition containing mor agonist and kor agonist, and uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 2645US11000518B2Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancerJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted May 11, 2021·0 cites·5 claims
- 2745US2016326230A1Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of sameShanghai hengrui pharmaceutical co ltd·Filed 2014·Application pending·0 cites
- 2844US2020054764A1Medical use of anti-c met antibody-cytotoxic drug conjugateSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Application pending·0 cites
- 2944US2021363266A1Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 3043US11471503B2Use of KOR agonist in combination with MOR agonist in preparing drug for treating painJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Oct 18, 2022·0 cites·20 claims
- 3143US11065239B2Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumorJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Jul 20, 2021·0 cites·20 claims
- 3243US2023099739A1Jak kinase inhibitor and preparation and application thereofMINGHUI PHARMACEUTICAL SHANGHAI LTD·Filed 2021·Application pending·0 cites
- 3342US2020131263A1Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 3440US12384786B2Cyclic molecules as Bruton's tyrosine kinase inhibitorMINGHUI PHARMACEUTICAL SHANGHAI LTD·Filed 2020·Granted Aug 12, 2025·0 cites·11 claims
- 3540US2019225698A1Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of sameJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
- 3636US12479922B2Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivityCYTOLYNX THERAPEUTICS HONG KONG LTD·Filed 2020·Granted Nov 25, 2025·0 cites·11 claims
- 3734US2019224189A1Use of tyrosine-kinase inhibitor in preparing pharmaceutical product for cancer treatmentJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
- 3833US2019358212A1Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drugJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guoqing Cao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →